Mr. Liang Lin reports

INSUJET DISTRIBUTION EXPANDS ACROSS FRANCE

Nugen Medical Devices Inc. has unveiled a dedicated French-language information and e-commerce site for InsuJet, the company's needle-free insulin delivery device.

Developed with Nugen's exclusive distributor, Sol-Millennium France, the platform gives people living with diabetes in France instant access to product details, educational resources and secure on-line purchasing. At checkout, patients may opt for nurse-led onboarding that supports them all the way to seamless enrolment in the recurring consumables program -- ensuring confident adoption and lasting adherence.

A growing market need

According to France's national health insurance (Assurance Maladie), diabetes remains a critical -- and growing -- public-health challenge: In 2022, 4.33 million people were living with diabetes -- a prevalence of 6.3 per cent. The economic impact is escalating just as quickly: Reimbursements tied to diabetes jumped from 7.6 billion euros in 2015 to more than 10 billion euros in 2022.

Complications account for a significant share of diabetes-related health care costs because most of the 92 per cent of patients who have Type 2 diabetes delay insulin start; 80 per cent of French physicians blame needle anxiety. By eliminating the needle for France's approximately four million Type 2 diabetics, InsuJet promotes earlier insulin use and delivers substantial savings to the national health system.

These figures highlight the urgent need for innovative, cost-effective solutions such as InsuJet's needle-free insulin delivery technology.

About InsuJet

Designed for adults and children (six years old and up), InsuJet delivers standard U-100 insulin through a precise high-pressure microjet through the nozzle that penetrates the skin without needles.

Users experience less anxiety, no sharps-disposal burden and simpler day-to-day diabetes management.

Clinical studies demonstrate faster insulin absorption, tighter glycaemic control and higher patient satisfaction versus traditional needles -- advances that directly address France's call for safer, more economical diabetes care.

Key features:

• Durability -- reusable for up to 5,000 injections (equal to 3.5 years at four injections per day);
• Universally compatible -- works with any U-100 insulin in three-millimetre cartridges, prefilled insulin pens or 10-millilitre vials;
• Needle-free convenience -- eliminates sharps containers and related waste;
• CE (Conformite Europeenne) marked -- compliant with European medical device standards;
• Broad usability -- approved for adults and children six years old and over.

Adoption and interest from the clinical community

The health care community has responded enthusiastically to the introduction of InsuJet. Officially prelaunched at the 2025 Congress of the Societe Francophone du Diabete (SFD) this past April, where it was named Innovation of the Year in Insulin Therapy, InsuJet attracted significant clinical interest. Numerous hospitals requested demonstrations, leading to two clinical evaluations at the Institut de Diabetologie et Nutrition du Centre (IDNC). These studies aim to support national reimbursement and further validate the clinical and economic benefits of needle-free insulin delivery.

About Nugen Medical Devices Inc.

Nugen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide.

We seek Safe Harbor.